論文・技術情報追加のお知らせ

1. Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

ラパチニブで皮膚系中心に新規有害事象シグナル検出

対象DB：FAERS

2. Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs.

VMAT2阻害活性と神経有害事象に明確な相関は確認されず

対象DB：FAERS

3. Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.

GLP-1作動薬で稀に重篤なウェルニッケ脳症が報告され注意必要

対象DB：FAERS

4. The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database.

大腸癌治療薬では心不全リスクがあり、特にアフリベルセプトやラムシルマブで注意が必要

対象DB：FAERS

5. Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.

チルゼパチドは早期に多彩な新規有害事象シグナルが示され、初期モニタリングが重要

対象DB：FAERS

6. Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system.

テトラサイクリン系は薬疹リスクが他抗菌薬より高い

対象DB：FAERS

7. Biliary disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

免疫チェックポイント阻害薬で重篤な胆道障害リスクが高い

対象DB：FAERS

8. Adverse events following Synflorix vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2024.

シンフロリックス接種後、小児で全身反応が多く注意が必要

対象DB：FAERS,VAERS

9. Corticosteroid Use and Atrial Fibrillation: Exploring Underlying Mechanisms, FAERS Disproportionality Analysis, and a Meta-Analysis of Clinical Studies.

ステロイド使用は用量・期間依存的に心房細動リスクを増加

対象DB：FAERS

10. Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System.

フィナステリド性機能障害報告はノセボ影響示唆

対象DB：FAERS

11. Impact of everolimus-based immunosuppression on transplant rejection or death in lung transplant recipients using the United States Food and Drug Administration Adverse Event Reporting System.

肺移植後でエベロリムス併用は拒絶や死亡報告が少ない可能性

対象DB：FAERS

12. Pharmacovigilance study and development of a clinical decision flowchart for personalized selection of trastuzumab, T-DXd, and T-DM1 in breast cancer patients.

HER2治療薬で副作用特性が異なり個別選択が重要

対象DB：FAERS

13. Evaluation of the association of pseudoaldosteronism with licorice-containing herbal medicine using the Japanese Adverse Drug Event Report (JADER) database.

甘草含有漢方で偽アルドステロン症リスクが用量依存的に増加

対象DB：JADER

14. Neurotrauma and multiple sclerosis: the silent catalyst - a systematic review and meta-analysis.

頭部外傷は多発性硬化症発症リスクを高める可能性

対象DB：JADER

15. Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan.

DPP-4阻害薬の類天疱瘡報告は注意改訂後に増加

対象DB：JADER

16. Emotional and behavioural symptoms in childhood (aged 8-14) and severity of mental illness outcomes in young adults: a retrospective observational study using cross-sectional data from electronic health records in the clinical practice research datalink (CPRD).

小児期の行動・情緒問題は若年期の重症精神疾患と関連

対象DB：CPRD

17. Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.

長時間型インスリンは腎症リスクを低下させなかった

対象DB：CPRD

18. Unveiling the Limits of Anticholinergic Burden Scales: A Study of Adverse Drug Reactions in the French Pharmacovigilance Database.

抗コリン薬副作用は尺度で過小評価され実態と乖離

対象DB：FPVD

19. Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study.

SGLT2阻害薬はNSAIDs併用時の急性腎障害リスクを低減

対象DB：DeSC

20. Unfilled Prescriptions in Japan: A 10-Year Retrospective Analysis.

日本で初回処方未受取は約5％で長期安定

対象DB：DeSC